Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (241-250 of 303) with videos related to

Pageof 31
Sort By:
Cancer Research and Treatment|January 6, 2017
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid CancerMin-Young Lee, Bo Mi Ku, Hae Su Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging systemByung Woo Jhun, Kyung-Jong Lee, Kyeongman Jeon, et al.
Cancer|October 16, 2023
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancerSehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS studyHyun Ae Jung, Tae Min Kim, Hye Ryun Kim, et al.
Genomics|February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatmentDonghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Anticancer Research|November 14, 2013
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patientsChi Hoon Maeng, Ho Yun Lee, Young Wook Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2015
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or ErlotinibJi Yun Lee, Jong-Mu Sun, Sung Hee Lim, et al.
Cancer|June 26, 2020
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapySehhoon Park, Joonho Shim, Peter G S Mortimer, et al.
European Journal of Immunology|June 9, 2020
MDSC subtypes and CD39 expression on CD8<sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLCJiae Koh, Youjin Kim, Kyoung Young Lee, et al.
Pageof 31

Showing results (241-250 of 303) with videos related to

Sort By:
Pageof 31
Cancer Research and Treatment|January 6, 2017
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid CancerMin-Young Lee, Bo Mi Ku, Hae Su Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging systemByung Woo Jhun, Kyung-Jong Lee, Kyeongman Jeon, et al.
Cancer|October 16, 2023
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancerSehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS studyHyun Ae Jung, Tae Min Kim, Hye Ryun Kim, et al.
Genomics|February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatmentDonghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Anticancer Research|November 14, 2013
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patientsChi Hoon Maeng, Ho Yun Lee, Young Wook Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2015
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or ErlotinibJi Yun Lee, Jong-Mu Sun, Sung Hee Lim, et al.
Cancer|June 26, 2020
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapySehhoon Park, Joonho Shim, Peter G S Mortimer, et al.
European Journal of Immunology|June 9, 2020
MDSC subtypes and CD39 expression on CD8<sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLCJiae Koh, Youjin Kim, Kyoung Young Lee, et al.
Pageof 31